Gahrton G, Tura S, Belanger C, Cavo M, Chapvis B, Ferrant A, Flesch M, Gore M, Gratwohl A, Gravett P J
Eur J Haematol Suppl. 1989;51:182-5. doi: 10.1111/j.1600-0609.1989.tb01514.x.
50 patients with a median age of 41 years (range 29-54) underwent allogenic bone marrow transplantation for multiple myeloma. 35 patients were on second-line treatment, and 15 on first-line treatment. 24 patients were considered refractory to previous treatment. 45 patients received marrow from HLA-matched sibling donors (3 of these from twin donors), and 5 from unrelated or related non-sibling donors. 21 patients entered complete remission, while 15 had persistent disease following repopulation of the marrow. 14 patients were not evaluable for remission status because of early transplantation-related death. The overall median survival from bone marrow transplantation was 27 months, with a projected long-term survival of 34%. Patients who were 40 yr of age or older had a survival that was not different from that of patients between 29 and 40 yr of age. The median disease-free survival of patients who entered complete remissions was 41 months. These patients tended to have a longer survival than patients with persistent disease following repopulation of the marrow. Allogeneic bone marrow transplantation appears to be a promising method for treatment of certain patients with multiple myeloma.
50例年龄中位数为41岁（范围29 - 54岁）的患者因多发性骨髓瘤接受了异基因骨髓移植。35例患者接受二线治疗，15例接受一线治疗。24例患者被认为对先前治疗无效。45例患者接受了来自人类白细胞抗原（HLA）匹配的同胞供者的骨髓（其中3例来自双胞胎供者），5例接受了来自非血缘或有血缘关系的非同胞供者的骨髓。21例患者进入完全缓解期，而15例在骨髓重建后仍有持续性疾病。14例患者因早期与移植相关的死亡而无法评估缓解状态。骨髓移植后的总体生存中位数为27个月，预计长期生存率为34%。40岁及以上患者的生存率与29至40岁患者的生存率无差异。进入完全缓解期的患者无病生存中位数为41个月。这些患者的生存期往往比骨髓重建后仍有持续性疾病的患者更长。异基因骨髓移植似乎是治疗某些多发性骨髓瘤患者的一种有前景的方法。
